Comparison of triple anti-platelet therapy (aspirin, clopidogrel, and cilostazol) and double anti-platelet therapy (aspirin and clopidogrel) on platelet aggregation in type 2 diabetic patients undergoing drug-eluting stent implantation
- PMID: 19997541
- PMCID: PMC2790129
- DOI: 10.4070/kcj.2009.39.11.462
Comparison of triple anti-platelet therapy (aspirin, clopidogrel, and cilostazol) and double anti-platelet therapy (aspirin and clopidogrel) on platelet aggregation in type 2 diabetic patients undergoing drug-eluting stent implantation
Abstract
Background and objectives: Triple anti-platelet therapy may produce more potent inhibition of platelet aggregation in patients undergoing coronary stent implantation. We tested whether this effect could be maintained in diabetic patients, where platelet reactivity is increased and the risk of stent thrombosis is higher.
Subjects and methods: Fifty five type 2 diabetic patients who had undergone drug-eluting stent (DES) implantation and chronic anti-platelet therapy (>1 month) were stratified according to the status of anti-platelet therapy. Platelet aggregation after adenosine diphosphate (ADP; 10 micromol/L and 20 micromol/L) stimulation was compared using light transmittance aggregometry between dual (aspirin plus clopidogrel, n=34) and triple therapy (aspirin, clopidogrel plus cilostazol, n=21) groups.
Results: The 2 groups had similar clinical and procedural characteristics. Maximal ADP-induced platelet aggregation was significantly lower in the triple therapy group than the dual therapy group (ADP 10 micromol/L, 37.1+/-15.4 vs. 28.3+/-11.8, p=0.03; ADP 20 micromol/L, 63.1+/-15.0 vs. 49.1+/-15.1, p=0.01), but there were no differences in diabetic treatment (oral hypoglycemic agent vs. insulin) or diabetic control {hemoglobin Alc (HbA1c) </=7 vs. HbA1c >7}.
Conclusion: Triple anti-platelet therapy showed more potent inhibition of maximal ADP induced platelet aggregation in type 2 diabetic patients receiving chronic anti-platelet therapy. This finding suggests that triple antiplatelet therapy may be more effective in preventing thrombotic complications after DES implantation in type 2 diabetic patients.
Keywords: Antiplatelet drugs; Diabetes mellitus; Platelet aggregation; Stents.
Figures

Similar articles
-
Effects of triple antiplatelet therapy (aspirin, clopidogrel, and cilostazol) on platelet aggregation and P-selectin expression in patients undergoing coronary artery stent implantation.Am J Cardiol. 2007 Aug 15;100(4):610-4. doi: 10.1016/j.amjcard.2007.03.070. Epub 2007 Jun 29. Am J Cardiol. 2007. PMID: 17697815 Clinical Trial.
-
[The effects of post coronary stenting triple antiplatelet therapies on platelet functions].Zhonghua Nei Ke Za Zhi. 2006 Aug;45(8):635-8. Zhonghua Nei Ke Za Zhi. 2006. PMID: 17074146 Clinical Trial. Chinese.
-
Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Diabetic Patients).J Am Coll Cardiol. 2008 Mar 25;51(12):1181-7. doi: 10.1016/j.jacc.2007.11.049. J Am Coll Cardiol. 2008. PMID: 18355656 Clinical Trial.
-
Comparison of on-treatment platelet reactivity between triple antiplatelet therapy with cilostazol and standard dual antiplatelet therapy in patients undergoing coronary interventions: a meta-analysis.J Cardiovasc Pharmacol Ther. 2013 Nov;18(6):533-43. doi: 10.1177/1074248413495971. Epub 2013 Jul 19. J Cardiovasc Pharmacol Ther. 2013. PMID: 23872509 Review.
-
Rationale and design of The Intracoronary Stenting and Antithrombotic Regimen-Testing of a six-week versus a six-month clopidogrel treatment Regimen In Patients with concomitant aspirin and oraL anticoagulant therapy following drug-Eluting stenting (ISAR-TRIPLE) study.Am Heart J. 2014 Apr;167(4):459-465.e1. doi: 10.1016/j.ahj.2014.01.005. Epub 2014 Jan 14. Am Heart J. 2014. PMID: 24655693 Review.
Cited by
-
Effects of Cilostazol and Aspirin on Diabetic Foot Ulcer and Peripheral Artery Disease: A Retrospective Study.Cureus. 2025 Mar 20;17(3):e80929. doi: 10.7759/cureus.80929. eCollection 2025 Mar. Cureus. 2025. PMID: 40255702 Free PMC article.
-
Clopidogrel-induced neutropenia after coronary stenting: is cilostazol a good alternative?Int J Vasc Med. 2011;2011:867964. doi: 10.1155/2011/867964. Epub 2011 Aug 11. Int J Vasc Med. 2011. PMID: 21860799 Free PMC article.
-
Fatal renal bleeding in a patient treated with aggressive antithrombotic therapy after recurrent coronary stent thrombosis.Korean Circ J. 2010 Jul;40(7):348-51. doi: 10.4070/kcj.2010.40.7.348. Epub 2010 Jul 26. Korean Circ J. 2010. PMID: 20664745 Free PMC article.
-
Optimal antithrombotic strategy in patients with atrial fibrillation after coronary stent implantation.Korean Circ J. 2011 Oct;41(10):578-82. doi: 10.4070/kcj.2011.41.10.578. Epub 2011 Oct 31. Korean Circ J. 2011. PMID: 22125556 Free PMC article.
-
The safety of triple antiplatelet therapy under thromboelastography guidance in patients undergoing stenting for ischemic cerebrovascular disease.J Neurointerv Surg. 2019 Apr;11(4):352-356. doi: 10.1136/neurintsurg-2018-013987. Epub 2018 Aug 12. J Neurointerv Surg. 2019. PMID: 30100558 Free PMC article.
References
-
- Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002;287:2570–2581. - PubMed
-
- Kim W, Jeong MH, Kim KH, et al. Long-term clinical and angiographic results of coronary stenting in diabetic patients. Korean Circ J. 2001;31:24–30.
-
- Iakovou I, Schmidt T, Bozizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005;293:2126–2130. - PubMed
-
- Colwell JA, Nesto RW. The platelet in diabetes: focus on prevention of ischemic events. Diabetes Care. 2003;26:2181–2188. - PubMed
-
- Vinik AI, Erbas T, Park TS, Nolan R, Pittenger GL. Platelet dysfunction in type 2 diabetes. Diabetes Care. 2001;24:1476–1485. - PubMed
LinkOut - more resources
Full Text Sources